So JPM is done and it was the least eventful one I can remember. I am still a little surprised that the sector has done this well. Usually post JPM we see a flood of secondaries and I suspect there will be an uptick in the next couple weeks. That being said we ended last […]
So I think JPM is a complete failure in terms of news. It is obviously a dud in terms of M&A. I do not remember the last time we had a JPM with zero mergers. There have been some with minor deals but it has been awhile since there have not been any. This actually […]
Yikes, what a boring start to JPM. I thought last year was sort of slow news and no big events sort of JPM but this is even worse. There is nothing bad that has been announced but if we thought that JPM would spark some life into the sector with big news, then we are […]
Despite the fact that we are mainly focused on the biotech sector, we have to keep an open eye on the overall markets and the correlation with the geopolitics situation in the US. While the SP-500 index is on tear since the 666.79 points back in March 2009, reaching an All-Time-High of 3826.69 points last […]
Founded in 2011, Chimera Research Group provides completely independent and actionable investment and trading ideas backed by comprehensive fundamental research and analysis for listed companies in the biotech and pharmaceutical sectors. Our coverage focuses on early stage companies with impending FDA decisions or clinical trial results but also includes mid-to-large cap bio-pharma companies where there exists specific catalysts. Our Trade Ideas are designed to maximize the risk reward profile. Our Research Reports outline the top up-and-coming catalysts that represent the best opportunities for traders and investors.
The biopharmaceutical sector offers significant opportunities to generate big returns yet can be risky and difficult to navigate.
Subscribe to Chimera Research Group and proceed with confidence.